Since 2011, pharmaceutical costs have increased exponentially, outpacing inflation.1 Recent research has shown an increasing frequency of prescription drug overpayments, or “clawbacks,” where an insured patient’s copayment exceeds the insurer’s cost for the drug. To date, clawbacks have been quantified for the most commonly used oral drugs across all medical disciplines, but clawbacks have not been assessed for topical drugs. The objective of this study was to investigate the prevalence and cost of clawbacks for topical prescription drugs.
Identify all potential conflicts of interest that might be relevant to your comment.
Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.
Err on the side of full disclosure.
If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.
Not all submitted comments are published. Please see our commenting policy for details.
Shumaker K, Maczuga S, Kirby J. Assessment of Overpayment for Topical Dermatological Drugs—Clawbacks. JAMA Dermatol. 2019;155(11):1315–1317. doi:10.1001/jamadermatol.2019.3078
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: